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ABSTRACT Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised,
double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the
efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.
Eligible subjects were adults with idiopathic pulmonary fibrosis of ,3 years duration and a histological
pattern of usual interstitial pneumonia on surgical lung biopsy. The primary objective was to demonstrate
that macitentan (10 mg once daily) positively affected forced vital capacity versus placebo.
Using a centralised system, 178 subjects were randomised (2:1) to macitentan (n5119) or placebo
(n559). The median change from baseline up to month 12 in forced vital capacity was -0.20 L in the
macitentan arm and -0.20 L in the placebo arm. Overall, no differences between treatments were observed
in pulmonary function tests or time to disease worsening or death. Median exposures to macitentan and
placebo were 14.5 months and 15.0 months, respectively. Alanine and/or aspartate aminotransferase
elevations over three times upper limit of normal arose in 3.4% of macitentan-treated subjects and 5.1% of
placebo recipients.
In conclusion, the primary objective was not met. Long-term exposure to macitentan was well tolerated
with a similar, low incidence of elevated hepatic aminotransferases in each treatment group.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease [1]. IPF occurs predominantly in
older adult males and is characterised by radiological and/or histopathological patterns of usual interstitial
pneumonia (UIP), progressive worsening of dyspnoea and lung function and a poor prognosis [1, 2]. A
limited number of studies have suggested potential benefits from some pharmacological agents in IPF
treatment [3–6].
While the pathogenesis of IPF is incompletely understood, the potent vasoconstrictor and growth factor
endothelin-1 has been implicated in the fibrogenic processes underlying the disease [7]. However, two
previously reported trials of the oral dual endothelin receptor antagonist (ERA) bosentan in subjects with
IPF did not meet their primary end-points [8, 9] and a trial of the single ERA ambrisentan was terminated
due to a lack of efficacy [10].
Macitentan, a novel dual ERA, has been shown to prevent the development of lung fibrosis in a rat model of
bleomycin-induced pulmonary fibrosis [11]. To investigate the efficacy and safety of macitentan in subjects
with IPF, the prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled, phase
II, proof-of-concept Macitentan USe in an Idiopathic Pulmonary Fibrosis Clinical (MUSIC) trial
(NCT00903331) was designed.
Material and methods
Study subjects
Subjects were eligible to participate in the trial if they were aged o18 years with a proven diagnosis of IPF,
according to the American Thoracic Society/European Respiratory Society statement [12], of ,3 years
duration, with surgical lung biopsy features of UIP.
During assessment for eligibility, prospective subjects were excluded prior to randomisation if they
exhibited any of the following: interstitial lung disease due to conditions other than IPF; extensive
honeycombing on baseline high-resolution computed tomography (as defined by the criteria used in the
Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial [9]); forced vital capacity (FVC) ,50% predicted
or ,1.2 L; diffusing capacity of the lung for carbon monoxide corrected for haemoglobin (DLCO) ,30%
pred; residual volume o120% pred; or obstructive lung disease (defined as forced expiratory volume in 1 s
(FEV1)/FVC ,0.70). A full list of exclusion criteria is available as online supplementary material.
In addition, subjects were ineligible for participation in the trial if, within 4 weeks of randomisation, they
received any of the following treatments: ERAs; oral corticosteroids (.20 mg?day-1 prednisone or
equivalent); immunosuppressive or cytotoxic drugs (including cyclophosphamide and azathioprine);
antifibrotic drugs (including pirfenidone, D-penicillamine, colchicine, tumour necrosis factor-a
antagonists, imatinib, interferon-c); N-acetylcysteine (.600 mg?day-1 prescribed chronically for IPF); or
oral anticoagulants (where prescribed for IPF).
The MUSIC trial was conducted in academic and community hospitals in selected countries and in
conformance with the principles of the Declaration of Helsinki. Approval from all relevant ethics
committees and institutional review boards was received prior to study start. Written, informed consent was
obtained from all subjects. The trial was registered at ClinicalTrials.gov (NCT00903331).
Study design
The MUSIC trial was a prospective, randomised, double-blind, multicentre, parallel-group, placebo-
controlled, phase II study. The primary objective was to demonstrate that macitentan (10 mg once daily)
positively affected FVC versus placebo. Secondary objectives were to evaluate the effects of macitentan on
the time to IPF worsening or death and to evaluate the safety and tolerability of macitentan in a population
of subjects with IPF.
Full details of the study assessments performed at each visit are available as online supplementary material.
In brief, subjects were assessed at screening, randomisation and every 4 months thereafter until the end of
the study.
Screening assessments included demographics, medical history, vital signs, concomitant medications,
laboratory tests, pulmonary function tests, resting arterial blood gas, assessment of high-resolution
computed tomography of the chest and histological analysis of surgical lung biopsy specimens.
At time of randomisation, subjects were assessed using the baseline dyspnoea index [13], vital signs, physical
examination, concomitant medications, FEV1, FVC, corrected DLCO and laboratory tests. Assessments at
INTERSTITIAL LUNG DISEASES | G. RAGHU ET AL.
DOI: 10.1183/09031936.00104612 1623
4-monthly intervals until the end of treatment included FEV1, FVC, corrected DLCO, transition dyspnoea
index (TDI), laboratory tests, concomitant medications and adverse events.
The end-of-study visit took place when the last randomised subject who did not discontinue treatment had
completed 12 months of therapy. At this visit, FEV1, FVC, corrected DLCO, TDI, concomitant medications
for IPF and disease-worsening events were assessed.
Measurements for the investigation of safety and tolerability were documented throughout the study with a
final assessment at 28 days after study drug discontinuation. Subjects were followed until the end of the
study even if they discontinued treatment.
The planned sample size for this trial was 156 subjects, with 104 subjects required to receive macitentan and
52 required to receive placebo. This sample size was considered necessary to detect with 80% power a
placebo-corrected mean reduction in FVC from baseline up to month 12 of o0.10 L; a parameter that was
expected to have a normal distribution with a standard deviation of 0.20 L.
Methods
Within 4 weeks of screening and using a centralised system (Interactive Voice/Web Response System;
S-Clinica, Brussels, Belgium), subjects were randomised 2:1 to oral macitentan (10 mg once daily in the
morning) or placebo. The first intake of study medication took place at the study centre, at the time of
randomisation and after successful completion of all assessments. Subjects could receive study medication
in addition to usual background therapy for IPF (if present and where permitted by the protocol);
background therapy was to remain at a constant dose throughout the investigational period.
Both tablets and packaging for macitentan and placebo were indistinguishable. Investigators, study staff,
subjects, monitors and the sponsor remained blinded to treatment assignment throughout the trial. Only
after study closure were randomisation codes made available for data analysis.
Analysis
Outcome measures
The primary efficacy end-point was the change in FVC from baseline up to month 12 for macitentan versus
placebo. Superiority of macitentan was defined as a placebo-corrected mean¡SD difference of
o0.10¡0.20 L.
The secondary efficacy end-point was the time to first occurrence of IPF worsening or death (all causes) up
to the end of study. IPF worsening was defined as 1) worsening of pulmonary function test (PFT) results
(i.e. showing a decrease from baseline in absolute FVC o10% and a decrease from baseline in absolute
corrected DLCO o15% and which were not refuted by a confirmatory test after o4 weeks) or 2) acute
respiratory decompensation of IPF (i.e. an unexplained rapid deterioration of a subject’s condition over a
period of ,4 weeks with an increasing shortness of breath requiring oxygen supplementation of
o5 L?min-1 to maintain a resting oxygen saturation o90% or arterial oxygen pressure o55 mmHg (at sea
level) or 50 mmHg (at high altitude)). Subjects who were unable to perform PFTs due to worsened IPF
were considered to have worsening results unless this was disproved by a subsequent assessment.
Exploratory efficacy end-points included: 1) the evaluation of TDI [13] up to month 12 and the between-
group difference in the numbers of subjects with TDI o1 up to month 12; 2) the change from baseline up
to month 12 in PFT results (specifically FEV1 and corrected DLCO); and 3) the change from baseline up to
month 12 in composite physiologic index [14]. The placebo-corrected change in FVC from baseline up to
month 12 in subpopulations of subjects grouped by baseline demographics and clinical characteristics
(specifically age, sex, location, FVC at baseline and use of oral IPF therapies at baseline) was also explored.
All exploratory end-points were defined a priori and before unblinding.
Statistical methods
Analysis of the primary efficacy end-point was performed on the ‘‘all-randomised set’’, which consisted of
all randomised subjects regardless of whether or not they received study medication. The change in FVC
from baseline up to month 12 was evaluated and the treatment comparison performed using the Wilcoxon
rank-sum test with asymptotic approximation to a t-distribution. The null hypothesis was that there was no
difference between interventions in the change from baseline up to month 12 in FVC, using a two-sided
0.05 type-I error level. No interim analyses of efficacy were conducted and there were no significant changes
to the study following its commencement. The primary efficacy analysis was repeated on a ‘‘per-protocol
set’’, which included all randomised subjects who were without major protocol deviations.
For the primary end-point analysis, in subjects for whom values from assessment of FVC were missing, the
following replacement rules were applied: 1) the last available post-baseline measurement obtained before
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month 12 was carried forward as a substitute for the missing value; 2) if a subject died before their
assessment, a value of 0.0 L was substituted for the missing values; 3) for subjects who were alive and
experienced disease worsening before month 12 but had no FVC assessment between the occurrence of the
event and month 12, the worst value for the FVC (defined as the greatest percentage decrease observed
between baseline and the considered time point for all subjects in the same analysis set) was imputed for the
missing value; 4) for subjects who were alive and experienced no disease worsening before month 12 but for
whom no post-baseline value was available, the mean percentage change at month 12 of observed values
(including carry-forward values) in the analysis set was applied to the baseline FVC value. An exploratory
repeated measurement analysis (random coefficient model) to investigate the changes in FVC from baseline
over the main study period was performed.
The secondary efficacy end-point was evaluated in the all-randomised set. Data were summarised by means
of Kaplan–Meier estimates of the proportion of subjects without the event at different time points displayed
with 95% confidence limits (CL). Log-rank testing and derivation of a hazard ratio up to the end of the
study were planned. Due to unmet assumptions on proportionality of hazards of treatments, post hoc
treatment effect estimates by log rank and hazard ratio up to month 12 were determined (censoring was
applied before the treatment mortality curves crossed).
Exploratory end-points were evaluated in the all-randomised set. Dichotomous variables were expressed as
incidence and relative risk of the macitentan group towards placebo with 95% CL. Continuous variables
were expressed using summary statistics (mean, median, standard deviation, range and 95% CL).
Safety analyses were performed on the all-randomised set, with data being summarised descriptively.
TABLE 1 Baseline demographics and clinical characteristics
Macitentan 10 mg Placebo
Subjects n 119 59
Male 84 (70.6) 37 (62.7)
Age years 66 (37–84) 64 (49–81)
65.1¡7.85 64.5¡6.32
IPF medical status
Duration of symptoms days 786 (151–4348) 771 (60–3180)
Duration since SLB-confirmed diagnosis days 213 (3–1870) 114 (2–1440)
Digital clubbing 23 (19.3) 8 (13.6)
Smoking
Never-smoker 47 (39.5) 22 (37.3)
Ex-smoker 67 (56.3) 37 (62.7)
Current smoker 5 (4.2) 0 (0.0)
Location
USA 37 (31.1) 18 (30.5)
Non-USA 82 (68.9) 41 (69.5)
FVC L 2.83 (1.24–5.42) 2.74 (1.36–6.61)
2.88¡0.83 2.79¡0.78
FVC % pred 76.1 (47.7–121.1) 73.8 (54.0–126.4)
76.5¡15.6 74.8¡14.6
Corrected DLCO mmol?kPa-1?min-1 4.16 (2.37–8.75) 4.13 (2.25–8.70)
4.55¡1.49 4.35¡1.32
Corrected DLCO % pred 46.5 (26.3 to 90.7)# 43.7 (30.7–76.1)
47.8¡13.4# 45.6¡11.2
Oral corticosteroid use 28 (23.5) 15 (25.4)
Daily dose mg prednisone equivalent 10.4¡3.42 12.1¡5.17
N-acetylcysteine use 19 (16.0) 13 (22.0)
Daily dose mg 600¡0.0 592¡27.7
Blood oxygenation mmHg
PaO2 77.9¡11.5
" 80.2¡15.0
PA–aO2 21.2¡10.8
+ 19.6¡11.31
Data are presented as n (%), median (range) or mean¡SD, unless otherwise stated. IPF: idiopathic pulmonary
fibrosis; SLB: surgical lung biopsy; FCV: forced vital capacity; DLCO: diffusing capacity of the lung for carbon
monoxide; % pred: % predicted; PaO2: arterial oxygen tension; PA–aO2: alveolar–arterial oxygen tension
difference. #: n5115; ": n5113; +: n5107; 1: n555.
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Results
Subject population
The trial started on May 19, 2009. A total of 178 subjects were enrolled from 48 centres in 12 countries
(Australia (n527), Canada (n515), France (n526), Germany (n513), Israel (n57), Italy (n58), Slovenia
(n52), South Africa (n52), Spain (n511), Sweden (n51), Turkey (n511) and USA (n555)). Of the 178
randomised subjects, 119 were allocated to macitentan and 59 to placebo. Baseline demographics and
clinical characteristics were well balanced between treatment groups (table 1). Disposition of the study
subjects is shown in figure 1. In accordance with the protocol, end of study was declared after the last
randomised subject had received 12 months of treatment. The trial was completed on June 30, 2011.
27 macitentan-treated subjects and 10 placebo recipients were excluded from the per-protocol set. In each
arm of the trial the principal reason for exclusion from the per-protocol set was a change in concomitant
medications for IPF without documented worsening of the underlying disease.
Allocated to macitentan (n=119)
   Received macitentan (n=119)
   Did not receive macitentan (n=0)
Study participation prematurely 
discontinued (n=18)
   Death (n=8)
   Consent withdrawn (n=8)
   Lung transplant (n=2)
Per-protocol set (n=92)
   Excluded from per-protocol set# (n=27)
      Change in IPF medication (n=16)
      Violation of entry criteria (n=5)
      FVC assessment nonacceptable (n=6)
      Randomisation violation (n=3)
      Compliance violation (n=2)
      Study treatment <4 weeks (n=1)
Per-protocol set (n=49)
   Excluded from per-protocol set# (n=10)
      Change in IPF medication (n=9)
      FVC assessment nonacceptable (n=1)
Analysed (n=119)
(all-randomised set, all-treated set)
Analysed (n=59)
(all-randomised set, all-treated set)
Study participation prematurely 
discontinued (n=5)
   Death (n=4)
   Consent withdrawn (n=1)
Allocated to placebo (n=59)
   Received placebo (n=59)
   Did not receive placebo (n=0)
Randomised (n=178)
Assessed for eligibility (n=300)
Completed study (n=101) Completed study (n=54)
Excluded (n=122)
Enrolment
Allocation
Follow-up
Analysis
FIGURE 1 Disposition of study subjects. IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity. #: subjects may
have exhibited more than one reason for exclusion.
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Efficacy measurements
Primary end-point: change from baseline up to month 12 in FVC
The median (95% CL) change from baseline up to month 12 in absolute FVC was -0.20 L (-0.29- -0.16 L) in
the macitentan arm and -0.20 L (-0.28- -0.13 L) in the placebo arm. The median (95% CL) treatment effect
of macitentan on FVC was 0.00 L (-0.09–0.08 L). The mean change from baseline up to month 12 in
absolute FVC, the mean treatment effect of macitentan on FVC and summary statistics pertaining to these
estimates are shown in online supplementary table S1).
When analysis of the primary end-point was repeated in the per-protocol set, results were consistent with
those of the all-randomised set (data not shown).
Time to first occurrence of IPF worsening or death
In total, 35 macitentan-treated subjects (29.4%) and 17 placebo recipients (28.8%) experienced at least one
occurrence of IPF worsening or death. An early trend favouring placebo was observed for time to IPF
worsening up to month 12 (post hoc HR 1.56, 95% CL 0.73–3.33; log-rank p50.2428) (fig. 2). This
difference was mainly driven by a numerically greater number of subjects in the macitentan arm who
exhibited early acute respiratory decompensation of IPF (seven (5.9%) subjects) versus placebo (one
(1.7%) subject).
Overall, in both treatment groups, the majority of events were recorded as IPF worsening with a
deterioration in PFT results (macitentan n525 (21.0%); placebo n514 (23.7%)). Death, when considered
for the analysis of the secondary end-point only, occurred in three (2.5%) subjects in the macitentan group
and two (3.4%) subjects in the placebo group.
Kaplan–Meier estimates of the time to first occurrence of IPF worsening or death at months 4, 8, 12, 20 and
24 are shown in online supplementary table S2. Results of the sensitivity analysis (random coefficient
model) conducted post hoc also showed no treatment effect of macitentan on the change in FVC over time
(data not shown). Data showing the causes of first occurrences of disease worsening and death up to month
12 and up to end of study are shown in online supplementary table S3.
Pulmonary function tests
The median changes from baseline up to month 12 in absolute FVC, absolute FEV1 and corrected DLCO are
shown in table 2. The median treatment difference between macitentan and placebo for FEV1 was small and
did not reach statistical significance (-0.03 L, 95% CL -0.10–0.04; p50.45). Similarly, for corrected DLCO
the median treatment difference between macitentan and placebo was small and not statistically significant
(0.03 mmol?kPa-1?min-1, 95% CL -0.17–0.23; p50.76).
The median change from baseline up to month 12 in the composite physiologic index is shown in table 3.
The median treatment difference between macitentan and placebo for the composite physiologic index was
small and did not reach statistical significance (-0.4, 95% CL -2.4–1.6; p50.66).
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FIGURE 2 Kaplan–Meier estimate for time to
first event of idiopathic pulmonary fibrosis
worsening or death. Data are Kaplan–Meier
estimates with 95% confidence limits at 4-
month intervals from subjects in the all-
randomised set.
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Data showing mean changes from baseline up to month 12 and mean treatment differences between
macitentan and placebo in absolute FEV1 and corrected DLCO are shown in online supplementary table S4.
Transition dyspnoea index
The median (95% CL) TDI at month 12 was -1.0 (-3.0–0.0) for macitentan-treated subjects and 0.0 (-2.0–
0.0) for placebo recipients. The number of subjects with TDI o1 in the macitentan arm was 27 (23.5%) and
in the placebo arm was 17 (28.8%); a relative risk reduction of 0.19 (95% CL -0.37–0.52; p50.47).
Efficacy in subject subgroups
Results of exploratory analyses of placebo-corrected changes from baseline up to month 12 in FVC among
subpopulations of subjects grouped by age, sex, location, FVC at baseline and use of oral IPF therapies at
baseline were similar to those observed in the primary analysis (fig. 3).
TABLE 2 Change from baseline up to month 12 in median absolute forced vital capacity (FVC),
absolute forced expiratory volume in 1 s (FEV1) and corrected diffusing capacity of the lung for
carbon monoxide (DLCO)
Macitentan 10 mg Placebo
Subjects n 119 59
FVC L
Baseline 2.83 (1.24–5.42) 2.74 (1.36–4.61)
Up to month 12 2.57 (0.00–5.16) 2.40 (0.00–4.67)
Change from baseline -0.20 (-2.86–0.42) -0.20 (-4.12–0.62)
FEV1# L
Baseline 2.34 (0.93–4.24) 2.23 (1.12–3.84)
Up to month 12 2.14 (0.00–4.34) 1.96 (0.00–3.85)
Change from baseline -0.18 (-2.47–0.35) -0.15 (-3.46–0.51)
Corrected DLCO# mmol?kPa-1?min-1
Baseline 4.18 (2.38–8.75) 4.13 (2.25–8.70)
Up to month 12 3.82 (0.00–8.46) 3.54 (0.00–7.27)
Change from baseline -0.40 (-6.64–1.07) -0.42 (-5.17–0.90)
Data are presented as median (range), unless otherwise stated. For the FVC analysis, eight (6.8%) subjects in
the macitentan group had no post-baseline data: for four (3.4%) subjects the worst values were imputed and
for four (3.4%) subjects the mean percentage change was imputed. In subjects with post-baseline data, five
(4.2%) macitentan-treated subjects and four (6.8%) placebo recipients had data carried forward and three
(2.5%) macitentan-treated subjects and two (3.4%) placebo recipients had worst values substituted for missing
data. For the FEV1 analysis, six (5.2%) subjects in the macitentan group had no post-baseline data and the
worst values were imputed. In subjects with post-baseline data, three (2.6%) macitentan-treated subjects and
four (6.8%) placebo recipients had data carried forward and three (2.6%) macitentan-treated subjects and two
(3.4%) placebo recipients had worst values substituted for missing data. For the DLCO analysis, four (3.5%)
subjects in the macitentan group had no post-baseline data and the worst value was imputed. In subjects with
post-baseline data, six (5.2%) macitentan-treated subjects and four (6.8%) placebo recipients had data carried
forward and four (3.5%) macitentan-treated subjects and three (5.1%) placebo recipients had worst values
substituted for missing data. #: n5115 in macitentan treatment arm.
TABLE 3 Change from baseline up to month 12 in composite physiologic index (CPI)
Macitentan 10 mg Placebo
Subjects n 115# 58#
CPI
Baseline 46.5 (1.3–73.7) 48.3 (17.4–70.5)
Up to month 12 50.7 (-9.2–80.9) 55.1 (17.5–80.9)
Change from baseline 3.7 (-16.7–49.5) 4.2 (-6.7–41.1)
Data are presented as median (range), unless otherwise stated. #: data from subjects in the all-treated set who
had a valid baseline measure of CPI.
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Safety and tolerability
The median (range) exposure to macitentan was 14.5 (0.0–24.6) months and to placebo was 15.0 (6.3–
24.3) months. A total of 91 (76.5%) macitentan-treated subjects and 48 (81.4%) placebo recipients were
exposed to investigational treatments for o12 months. From the beginning of treatment until up to
28 days after study drug discontinuation, 116 subjects in the macitentan group (97.5%) and 58 subjects in
the placebo group (98.3%) experienced at least one adverse event. Adverse events occurring in o10% of
macitentan-treated subjects are shown in table 4. A total of 15 (12.6%) macitentan-treated subjects and
seven (11.9%) placebo recipients experienced adverse events that led to the premature discontinuation of
study treatment. 37 (31.1%) macitentan-treated subjects and 20 (33.9%) placebo recipients experienced at
least one serious adverse event. The most common serious adverse events are shown in table 5. In total,
3.4% of macitentan-treated subjects and 5.1% of placebo recipients exhibited alanine and/or aspartate
aminotransferase elevations over three times the upper limit of normal. Observations following other
assessments of the tolerability of investigational treatments are available as online supplementary material.
In total, 13 subjects died during treatment or up to 28 days after the discontinuation of study drug: nine
(7.6%) subjects in the macitentan arm and four (6.8%) in the placebo arm. The most common causes of
death were IPF worsening (macitentan n52 (1.7%) and placebo n54 (6.8%)) and respiratory failure
(macitentan n53 (2.5%) and placebo n51 (1.7%)).
All subjects 119 59 0.00
-0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4
Favours placebo Favours macitentan
-0.09–0.08
Age years
Macitentan 
n
Placebo
n
Median
L
95% CL
 ≤ median (65)
Sex
58 34 0.07 -0.05–0.18
Male 84 37 0.03 -0.08–0.16
Female 35 22 -0.04 -0.15–0.07
Location
USA 37 18 0.05 -0.15–0.26
Non-USA 82 41 -0.02 -0.11–0.07
FVC at baseline L
 ≤ median (2.8) 57 32 0.02 -0.11–0.12
 > median (2.8) 62 27 -0.01 -0.15–0.12
Oral IPF therapies at baseline
Yes 37 19 0.14 -0.01–0.29
No 82 40 -0.07 -0.17–0.04
 > median (65) 61 25 -0.08 -0.22–0.04
FIGURE 3 Placebo-corrected median changes from baseline up to month 12 in forced vital capacity (FVC) in different subpopulations of study subjects. Data are
from subjects in the all-randomised set. IPF: idiopathic pulmonary fibrosis.
TABLE 4 Adverse events occurring in o10% of macitentan-treated subjects
Macitentan 10 mg Placebo
Subjects 119 59
Worsening of IPF 25 (21.0) 15 (25.4)
Dyspnoea 24 (20.2) 9 (15.3)
Cough 22 (18.5) 22 (35.6)
Upper respiratory tract infection 20 (16.8) 12 (20.3)
Bronchitis 16 (13.4) 9 (15.3)
Peripheral oedema 14 (11.8) 4 (6.8)
Anaemia 13 (10.9) 0 (0.0)
Data are presented as n or n (%). Data are from subjects in the all-randomised set. IPF: idiopathic pulmonary
fibrosis.
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Discussion
The MUSIC trial was a prospective, randomised, double-blind, multicentre, parallel-group, placebo-
controlled, phase II proof-of-concept study to investigate the efficacy and safety of the dual ERA,
macitentan, among study subjects with histologically proven IPF. The primary objective of the MUSIC trial,
to demonstrate that macitentan 10 mg once daily positively affected FVC versus placebo, was not met: no
significant difference between treatments could be discerned in the primary end-point of change from
baseline up to month 12 in FVC. In addition, no differences were observed between treatment groups in any
of the secondary measures including time to IPF worsening or death and in exploratory investigations of
treatment-related changes in PFT results. Long-term exposure to macitentan 10 mg once daily was well
tolerated, with an incidence of elevated hepatic aminotransferases that was similar to placebo.
While two previous trials of the dual ERA bosentan in subjects with IPF did not meet their primary end-
points [8, 9] and one trial of the single ERA ambrisentan was terminated due to a lack of efficacy [10], some
beneficial effects of bosentan treatment were observed in dyspnoea and health-related quality of life in a
subset of subjects who underwent surgical lung biopsy for diagnosis of IPF [8, 15]. The MUSIC trial, which
was initiated before the results of the BUILD-3 trial of bosentan [9] were available for analysis, provided an
opportunity to investigate the efficacy and tolerability of the dual ERA, macitentan, in a study population of
subjects with IPF causing a mild-to-moderate impairment in pulmonary function.
In this trial, treatment of subjects with the dual ERA macitentan was well tolerated. More than three-
quarters of the subjects in the macitentan treatment arm were exposed to the drug for o12 months. The
profile of adverse events observed in macitentan-treated subjects was similar to that seen in the placebo
group, especially with respect to the low rates of alanine and/or aspartate aminotransferase elevations over
three times the upper limit of normal. A greater proportion of subjects treated with macitentan versus
placebo exhibited peripheral oedema and anaemia. Fluid retention and anaemia are known to be associated
with ERAs as a class of agents in general, with increased risks of these events having been reported
previously in subjects with pulmonary arterial hypertension as well as chronic heart failure [16–21]. There
was no difference between the two treatment arms with regards to the incidence of death; rather, the
observed difference in risk between the groups up to month 12 was mainly driven by acute exacerbation.
The reason for this is not known. The observed lower rate of cough among macitentan-treated subjects
versus placebo recipients is also noteworthy, although we have no explanation for this.
In the present trial, the change from baseline up to month 12 in FVC was selected as the primary end-point.
This end-point was selected since FVC and other resting PFT results are used routinely in the management
of IPF. Furthermore, longitudinal decreases in FVC have been shown to be significant prognostic indicators
in IPF in several studies [22–25]. One exploratory study showed a possible prognostic value of decreases in
FVC of o5% over 3 months [26]. Another group estimated the minimal clinically important difference in
FVC over a 24-week period to be between 2% and 6% [25]. The selection of a mean relative difference
in FVC between treatment arms of 0.10 L and a standard deviation of 0.20 L were considered, based on
such reports [25, 26], to approximate a minimal clinically significant difference. The direction and
magnitude of longitudinal changes in FVC and corrected DLCO observed in the MUSIC trial readily mirror
those observed in several other studies in subjects with IPF [8, 9, 27, 28]. Similarly, the median increase
from baseline up to month 12 in composite physiologic index observed in the present study was of a similar
order of magnitude to that reported elsewhere among placebo recipients over a similar study duration [29].
TABLE 5 Serious adverse events occurring in more than one macitentan-treated subject
Macitentan 10 mg Placebo
Subjects 119 59
IPF worsening 10 (8.4) 6 (10.2)
Pneumonia 6 (5.0) 2 (3.4)
Respiratory failure 4 (3.4) 2 (3.4)
Hypoxia 3 (2.5) 2 (3.4)
Acute respiratory failure 2 (1.7) 1 (1.7)
Thrombocytopenia 2 (1.7) 0 (0.0)
Data are presented as n or n (%). Data are from subjects in the all-randomised set. IPF: idiopathic pulmonary
fibrosis.
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Endothelin-1 has been implicated and may contribute to the fibrogenic processes underlying IPF [7].
However, efficacy could not be demonstrated in several clinical trials that investigated single and dual ERAs
in subjects with IPF [8–10], including the present trial. Since IPF is a fibroproliferative disease in which
several pathogenic mechanisms are implicated, it is plausible that the key to successful treatment may
involve a combination of therapies targeting multiple pathways [30].
We acknowledge that the MUSIC trial had certain limitations. FVC is a reliable and responsive measure of
clinical status in IPF, in which a decline of 2–6% pertains to clinical importance [25]. However, FVC is not
fully validated as a surrogate measure for more meaningful outcomes, including survival [31]. As a result,
the choice of FVC as the primary end-point in this phase II trial may be considered to be disadvantageous
by some, in comparison with all-cause, nonelective hospitalisation or all-cause mortality [31]. The potential
for variability within assessments of PFTs may also represent a limitation in the choice of a physiological
end-point. In addition, due to unmet assumptions on proportionality of hazards of treatments, treatment
effect estimates in the time-to-event analysis were determined post hoc. Furthermore, the lack of a dose-
finding study meant that we were unable to ascertain the potential effects, if any, of higher doses of
macitentan among the subjects who participated in the trial.
In conclusion, the primary objective of the MUSIC trial, to determine if macitentan positively affected the
change in FVC from baseline up to month 12 versus placebo, was not met. No differences between
treatment groups were observed in any of the secondary or exploratory end-points. Long-term exposure
to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in
each treatment group.
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